Emcure Pharma Shares May Rally Up To 33%, Says MOFSL On Strong Growth Outlook; Check Target Price

Motilal Oswal expects Emcure to deliver a revenue CAGR of 15.2% over FY26-28E, driven by stable growth across segments, with domestic formulation and international business projected to grow at a CAGR of 12.4% and 17.4%, respectively.
Read the full story on NDTV Profit Opens ndtvprofit.com in a new tab
This is a short summary of a story published by NDTV Profit, shown with a link to the original. The full story, photo and reporting belong to NDTV Profit.












